Incidence of Audiological Adverse Effects Induced by COVID-19 Vaccines: A Preliminary Study

Ciorba, Andrea; Bianchini, Chiara; Caranti, Alberto; Skarżyński, Piotr H.; Pelucchi, Stefano; Hatzopoulos, Stavros

doi:10.1177/01455613211048975

Cited by 5 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another case series have reported the transient sudden unilateral tinnitus after BNT162b2 mRNA-vaccine (e.g., pfizer), which resolved rapidly in 2 out of 3 cases (63). Recently, many case reports have reported a prevalence of sudden hearing loss and tinnitus after the COVID-19 vaccinations (64)(65)(66)(67)(68).…”

Section: Auditory Manifestationsmentioning

confidence: 99%

Vestibular Cochlear Manifestations in COVID-19 Cases

2022

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a high transmissible infectious disease that primarily impacts the respiratory system and leads to death as it worsens. Ever since the World Health Organization declared the disease as a global pandemic, the pathophysiology, clinical manifestations, and disease prognosis has been discussed in various literature. In addition to impaired respiratory health, the symptoms also indicated the involvement of the cardiovascular and neurological system after SARS-CoV-2 infection. Despite the pulmonary, cardiovascular, and neurological complications, many reports also revealed the prevalence of vestibulocochlear symptoms like dizziness, vertigo, vestibular neuritis, sudden sensorineural hearing loss, and tinnitus. Though many clinical reports and scientific reviews reported the vestibular and cochlear impairments associated with coronavirus disease 2019 (COVID-19) infection, the underlying pathological mechanisms are still unclear and unexplored. In this review, we discussed the published clinical reports, research articles, and literature reviews related to vestibulocochlear manifestations following SARS-CoV-2 infections. We also summarized the current knowledge about the prevalence, epidemiological and clinical features, and potential pathological mechanisms related to vestibular and cochlear manifestations resulting from COVID-19 infections.

show abstract

Section: Auditory Manifestationsmentioning

confidence: 99%

Vestibular Cochlear Manifestations in COVID-19 Cases

2022

View full text Add to dashboard Cite

show abstract

“…Post‐vaccination otologic symptoms observed within 30 days of COVID‐19 vaccination included tinnitus, hearing loss, dizziness, or vertigo. 5 , 6 Earlier this year, 555 cases of sudden sensorineural hearing loss after COVID‐19 vaccination were reported in the North American Vaccine Related Adverse Effects System (VAERS) were investigated and no association was found between sudden sensorineural hearing loss and vaccination. 7 Symptom patterns and potential pathophysiologic mechanisms for post‐vaccine tinnitus were discussed in a recent review of over 12,000 cases of tinnitus post‐COVID‐19 vaccination, reported by the CDC.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of New‐Onset Tinnitus after COVID‐19 Vaccination with Comparison to Other Vaccinations

et al. 2022

View full text Add to dashboard Cite

Objective To investigate how often patients are diagnosed with new‐onset tinnitus within 21 days after COVID‐19 vaccination in comparison to after three other common vaccinations: influenza, Tdap (tetanus, diphtheria, and acellular pertussis), and polysaccharide pneumococcus. Methods The TriNetX Analytics Network, a federated health research network that aggregates the de‐identified electronic health record (EHR) data of over 78 million patients, was queried for patients receiving each vaccination. Instances of new‐onset tinnitus within 21 days of vaccination were recorded and reported. Results Out of 2,575,235 patients receiving a first dose of the mRNA COVID‐19 vaccine without any prior tinnitus diagnosis, 0.038% (95% CI: 0.036%–0.041%) of patients had a new diagnosis of tinnitus within 21 days. There was a higher risk of a new tinnitus diagnosis after the influenza vaccine (RR: 1.95, 95% CI: 1.72–2.21), Tdap vaccine (RR: 2.36, 95% CI: 1.93–2.89), and pneumococcal vaccine (RR: 1.97, 95% CI: 1.48–2.64) than after the first dose of the COVID‐19 vaccine. There was a lower risk of a new tinnitus diagnosis after the second dose of COVID‐19 than after the first dose (RR: 0.80, 95% CI: 0.71–0.91). Conclusion The rate of newly diagnosed tinnitus acutely after the first dose of the COVID‐19 vaccine is very low. There was a higher risk of newly diagnosed tinnitus after influenza, Tdap, and pneumococcal vaccinations than after the COVID‐19 vaccine. The present findings can help to address COVID‐19 vaccine hesitancy during the ongoing pandemic. Level of Evidence Level 3 Laryngoscope , 2022

show abstract

“…Both studies suggested that previous otologic diagnoses may result in a higher incidence of post-vaccination adverse effects. A further study by Ciorba et al 22 reported a higher incidence of post-vaccination vertigo (.96%) compared with tinnitus (.11%) in Italy. Formeister et al 14 found that the incidence of sudden sensorineural hearing loss was similar postvaccination to that expected in the general population.…”

Section: Discussionmentioning

confidence: 88%

“…A further study by Ciorba et al . 22 reported a higher incidence of post-vaccination vertigo (.96%) compared with tinnitus (.11%) in Italy. Formeister et al .…”

Section: Discussionmentioning

confidence: 94%

Adverse COVID-19 vaccination effects in Finnish patients with Ménière’s disease: a cross-sectional study

et al. 2022

View full text Add to dashboard Cite

Background: The association between reporting adverse coronavirus disease 2019 (COVID-19) vaccination effects and those with a history of audiovestibular difficulties is unknown. The aim of this research is therefore to investigate adverse vaccination effects in adults with a history of Ménière’s disease. Specifically, the incidence of adverse effects, the factors associated with those reporting adverse effects and the relationship between the reporting of audiovestibular and other adverse effects. Methods: A mixed-methods exploratory cross-sectional survey study design was used. Data were collected from 333 members of the Finnish Ménière Association. The survey was designed to obtain demographic information that may be associated with having adverse effects or not, vaccination-specific information and adverse vaccination effects. Both health and audiovestibular adverse events were identified. Data analysis included comparing those reporting and not reporting adverse vaccination effects. Results: The mean age was 63 years with 81% being female. Of the 327 respondents who had one of the COVID-19 vaccinations (Comirnatry/ Pfizer, Astra Zeneca, or Moderna), 203 (62%) reported no adverse effects. The type of or number of vaccinations were not related to the reporting of adverse effects. The most frequently reported adverse effects were injection site tenderness (38%), arm pain (21%), fever (15%) and headaches (15%). Post-vaccination tinnitus and vertigo (both 7%) were the most frequently reported audiovestibular-related symptoms, followed by aural fullness (6%) and hearing loss (4%). Those reporting previous pre-vaccination vertigo were more likely to have post-vaccination vertigo. The presence of post-vaccination tinnitus, hearing loss, and aural fullness, predicted the presence of post-vaccination vertigo. Conclusions: A small proportion of patients with a history of Ménière’s disease may experience adverse post-vaccination effects. Further research is required to explore whether adverse post-vaccination audiovestibular effects are more prevalent in those with a history of otological disorders compared with the general population.

show abstract

Incidence of Audiological Adverse Effects Induced by COVID-19 Vaccines: A Preliminary Study

Cited by 5 publications

References 3 publications

Vestibular Cochlear Manifestations in COVID-19 Cases

Vestibular Cochlear Manifestations in COVID-19 Cases

Prevalence of New‐Onset Tinnitus after COVID‐19 Vaccination with Comparison to Other Vaccinations

Adverse COVID-19 vaccination effects in Finnish patients with Ménière’s disease: a cross-sectional study

Contact Info

Product

Resources

About